B-cell–driven relapse and anti-CD20 rescue therapy after Alemtuzumab in RRMS: case report and literature review
BackgroundAlemtuzumab is an immune reconstitution therapy (IRT) approved for highly active relapsing–remitting multiple sclerosis (RRMS). Notably, the differential reconstitution of B and T cells after alemtuzumab may trigger paradoxical B–cell–mediate…